Report: Biopharma’s class of 2013 is laden with blockbusters

Damian Garde While 2013's number of approved drugs fell short of 2012's record haul, the class is likely to more than make up for that disparity in the dollar column, according ...

Giving letter grades for 2013 pharma performance

Eric Palmer Anyone can judge drugmakers' annual results by the numbers: top line, bottom line, growth, earnings or some combination of financial markers. It's more daring to ...

Most-recognized brands: Anti-infectives, December 2013

joshua.slatko The most-recognized anti-infective brand in North America is Cipro. The brand was most-recognized by 7 percent of physicians in a survey conducted by Brand Institute ...

Eylea growth slows a bit, but Regeneron hikes 2013 forecast

Tracy Staton Regeneron once again beat expectations with its quarterly earnings. And once again, the company raised its forecast for Eylea, the vision-loss drug that's fueling much ...

InterMune Reports Third Quarter 2013 Financial Results And Business Highlights

barbara.lempert — Reports 8th Consecutive Quarter of Esbriet Revenue Growth — BRISBANE, Calif., Oct. 30, 2013 /PRNewswire/ — InterMune, Inc. (NASDAQ: ITMN) today ...

Karo Bio Announces 2013 Interim Report

mia.burns INTERIM REPORT JANUARY-SEPTEMBER 2013 The January–September period and the third quarter 2013 in brief Net sales amounted to MSEK 37.4 (24.6), whereof the third quarter ...

FDA’s 2013 approvals record falls short of 2012 pace

Tracy Staton The good news: The FDA approved 18 new drugs during the first 8 months of this year. The not-so-good news: Last year, during the same time frame, the agency blessed 22 ...

With $29B in deals so far, 2013 shaping up as big M&A year

Eric Palmer With Valeant Pharmaceuticals forking over $ 8.7 billion for eye-care giant Bausch + Lomb and Amgen's $ 10.4 billion deal for Onyx Pharmaceuticals, this could be a ...

Adocia: Activity and results for the first half of 2013

barbara.lempert Intensification of R&D activity ahead of the launch of three clinical trials for insulin projects, starting in the second half of 2013 Net result of EUR -4.6 million ...

Facts and figures, August 2013

chris.truelove Close to 70 percent of Americans are on at least one prescription drug, and more than half take two drugs, according to Mayo Clinic and Olmsted Medical Center researchers. ...

Most-recognized gastrointestinal brands, August 2013

chris.truelove The most-recognized gastrointestinal brand in North America is Prilosec. The brand was most recognized by 11.5 percent of physicians in a survey conducted by Brand Institute ...

iCo Therapeutics Announces Second Quarter 2013 Financial Results

barbara.lempert VANCOUVER, Aug. 26, 2013 /CNW/ – iCo Therapeutics (TSX-V: ICO), today reported financial results for the quarter ended June 30, 2013. Amounts, unless specified ...
Page 1 of 1012345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS